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Abstract
Those who suffer from infertility, either due to a congenital or acquired cause and cannot or are opposed to other means, such as sur-
rogacy or adoption, to have a child, are potential candidates for uterine transplantation .  Uterine transplantation is a form of allograft 
transplantation, meaning that it is a transplant of tissue from a donor who is genetically different from the recipient .  Additionally, it 
is a vascularized transplant, including donor blood vessels that will be sutured to the vasculature of the recipient (Testa et al . 2017) . 
This procedure has been attempted around the globe with varying levels of success ranging from delivery of a healthy child to 
necrosis of the graft and rejection of the transplanted tissue.  While there does not seem to be one specific reason that can account 
for the rejection of a uterus transplant, the main factor responsible for failure is problems with arterial inflow or venous outflow in 
the recipient . Other potential factors that may contribute include cervix-vaginal size differences between donor uterus and recipient, 
pathology of the donated uterus, immunosuppressants, and wait time from transplant to embryo transfer .  Advancements in robotic 
assisted hysterectomy to procure the donor uterus, using ovarian veins instead of uterine veins for venous outflow, and deceased 
donor uteri instead of living donor uteri are all promising ways that can streamline the transplant process and help transition the 
experimental procedure of uterine transplantation to an accepted clinical one .
Uterine Transplantation: A Review of Some of the 
Factors that Account for the Success or Failure of this 
Experimental Procedure
Rachel Stern
Rachel  Stern will graduate with an Honors Bachelor of Science degree in Biology in January 2021.
Introduction
Uterine transplantation is a procedure where a uterus 
from either a live or deceased donor is surgically implant-
ed temporarily in a recipient, in order that the recipi-
ent can carry her own child in the transplanted uterus. 
The transplanted uterus is subsequently removed, either 
when a baby is born, if the pregnancy is terminated due 
to complications, or due to rejection of the transplant. 
Uterine Transplantation is an innovative treatment for 
those who are unable to carry a fetus in their own re-
spective uteri, either due to a congenital disorder, such 
as the absence of or an underdeveloped uterus, hyster-
ectomy, due to disease, cancer, endometriosis,  elective 
hysterectomy, or for transgender individuals who do not 
have a uterus (Testa et al., 2017).  Since uterine transplan-
tation is not considered a life-saving procedure, many are 
ethically opposed to the promotion and investment into 
such an experimental and costly surgery.
In this paper we will try to determine if the uterus 
can be transplanted successfully with childbearing results, 
and which factors are responsible for the rejection of a 
uterus transplant.
Materials and Methods
The Information contained in this review was found by 
searching the Touro online library general search, Ebsco, 
and Proquest databases using key terms such as “uterine 
transplantation.”  Pubmed and Google Scholar were also 
searched utilizing similar key words and phrases.
Candidates for Uterine Transplantation
People who express interest in uterus transplants gener-
ally suffer from what is known as uterine factor infertility, 
UFI (Arian et al., 2017), also known as absolute uterine 
factor infertility, AUI (Branstrom et al., 2020),  This can be 
due to a congenital cause, such as a condition known as 
Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), or 
Mullerian agenesis, which is caused by the “underdevel-
opment of the Mullerian duct, with resultant agenesis or 
atresia of the vagina, uterus, or both” (Oelschlager, 2018). 
Agenesis refers to the failure during embryological devel-
opment of an organ and atresia is where there is either 
an obstruction to the lumen, or an opening is abnormally 
narrowed. Since the Mullerian duct in utero is responsible 
for the development of the uterus, fallopian tubes, cervix, 
and the upper part of the vagina, when it fails to devel-
op in MRKH, all those structures, aside from the ovaries, 
are affected, and this often results in infertility.  Patients 
with MRKH are good candidates for uterine transplan-
tation because they have functioning ovaries, which are 
not included in the uterus transplant. Their oocytes can 
be extracted for in vitro fertilization, and they can have 
a biological child of their own genetics. Another class of 
those who are interested in uterine transplants include 
those who have absolute uterine factor infertility due to 
an acquired cause which resulted in hysterectomy, such 
as fibroid tumors, endometriosis, chronic pain, abnormal 
bleeding, malignancy, and obstetric complications.  In one 
study, out of the 239 people screened, one third sought 
treatment due to congenital UFI, while the other two 
thirds had acquired UFI.  Of the acquired group, half were 
due to benign conditions, 25.3% were due to gynecologic 
malignancies, and 24.7% had had prior obstetric compli-
cations that resulted in hysterectomy.  Although there 
were five transgender and one intersex individual, they 
were not included because they did not fit the inclusion 
criteria of the screening (Arian et al., 2017).  In anoth-
er 2017 study, candidates similarly included those with 
MRKH, acquired conditions such as irreversible intra-
uterine adhesions, fibromas that could not be operated 
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on, and those who had lost their uterus from either be-
nign or malignant pathologies or postpartum complica-
tions (Testa et al., 2017).
Donor Eligibility
Different studies had varied qualifications included in their 
inclusion criteria.  Firstly, age was a consideration. In one 
study, age was determined to be from 40-60, though those 
under the age of forty were considered if a candidate had 
successful pregnancies in the past and did not want to have 
another pregnancy in the future (Testa et al., 2017).  Similarly, 
in other studies, with successful live-birth outcomes, a 32 
year old uterus was used, having borne 2 children prior to 
transplantation (Testa et al., 2018), and a 24 year old nul-
ligravid uterus was also used in successful transplantation 
(Chmel et al., 2019). However, in the first successful trans-
plant in 2014 that resulted in childbirth, a 62 year old uterus 
was used, and another a successful live birth resulted from 
a 63 year-old uterus at the time of birth, indicating that al-
though older uteri are not necessarily considered ideal, they 
have yielded live births.  (Brannstrom et al., 2020).  Since 
often enough recipient’s mothers want to be donors for 
their daughters, in some studies an older upper limit is given 
at 55-65 years of age (Kisu et al., 2018).
Additional donor requirements in some studies includ-
ed criteria such as testing negative for gonorrhea, chla-
mydia, syphilis and HPV, or previous vaccination against 
HPV.  Previous history of HSV-2 was considered if there 
were no current symptoms, and previous HPV was con-
sidered as long as a negative history was shown since 
the case of HPV. Last, one prior full-term live birth was a 
qualification (Testa et al., 2017).
Other requirements included normal-shaped uteri, 
proper perfusion through uterine vasculature, and the ab-
sence of uterine damage or disease  (Chmel et al., 2019). 
Nulliparous, Nulligravid, or Multiparous Donor Uterus
In choosing between a nulligravid uterus, one that has 
never carried a fetus, a nulliparous uterus, a uterus that has 
never born offspring, and a multiparous uterus, one that 
has born offspring, different studies included multiparity in 
the inclusion criteria while others did not.  According to a 
2019 study using a nulliparous deceased donor, nulliparity 
was considered an advantage in terms of graft recovery be-
cause the uterine veins and arteries were straight and not 
varicose, as opposed to what they noted with multiparous 
donors (Chmel et al., 2019).  However, that was an ob-
servation made using few subjects, and would need to be 
further investigated to determine if a significant difference 
between the straightness of vasculature exists between 
nulliparous and multiparous uteri.
Live vs. Deceased Donor
Before investigating the differences between a living as 
opposed to a deceased donor, it is important to define 
who is considered “deceased.”  In this paper, deceased is 
used to mean brain-dead.
There are certain advantages to using a deceased 
donor over a live donor.  Firstly, using a live donor to 
procure a graft includes certain risks associated with any 
surgical procedure, such as the use of anesthesia, and sur-
gery, and specifically possible urological, psychological or 
sexual dysfunction that may result, which are not consid-
erations that need to be taken with a deceased donor. 
Secondly more radical surgical dissection can be done 
using a deceased donor than a live donor, which enables 
surgeons to procure larger vessels, decreasing the risk 
of graft thrombosis. Additionally, a longer vaginal cuff can 
be procured from a deceased donor, allowing a better 
vaginal–vaginal anastomosis between the donated uterus 
and the recipient’s vagina (Chmel et al., 2019).
A clear disadvantage of using a deceased donor is the 
practicality; the nature by which deceased donor uteri 
become available is unpredictable.  Also, multidisciplinary 
teams and the recipient must go to the location of the 
donor.  Moreover, in many countries, physicians have less 
access to deceased vascularized composite allografts, and 
there is more restricted access to deceased donor uteri 
due to the complicated nature of surrogate consent if the 
deceased has not expressly stated the desire to donate 
before death (Chmel et al., 2019).
However, new innovations in procurement of the donor 
uterus, such as using robotically-assisted minimally invasive 
procedures, can likely decrease risks to live donors by min-
imizing tissue trauma and bleeding compared to open sur-
gery, which would favor using live donor uteri (Brannstrom 
et al., 2020).  In one minimally invasive, robotic surgery, the 
estimated blood loss of the donor was 400 mL, compared 
to the researchers previous surgeries using laparotomy in 
nine cases, which ranged from estimated blood loss val-
ues between 300-2400 mL, with an average of 920 mL 
(Brannstrom et al., 2020).   Using robotic technology can 
also provide more dexterity and seven degrees of free-
dom for the surgeon, not to mention micro-suturing can 
be done more efficiently through laparoscopic ports (Wei 
et al., 2017).  Also, minimally invasive robotic procedures 
can minimize both surgery and recovery time for the 
donor (Carbonnel et al., 2020).  Surgery time in one ro-
botic assisted surgery took 6 hours, which is the shortest 
surgery duration time recorded for uterus procurement 
for transplant.  That may be partially due to the choice of 
vasculature that the researchers procured with the graft, 
but nonetheless they were able to drastically reduce 
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surgical time (Wei et al., 2017).  In addition to a reduction 
in bleeding and trauma, minimally invasive surgery yields 
better cosmetic results, which may influence a candidate’s 
readiness to donate (Carbonnel et al.,  2020).
Steps involved in Uterine Transplantation
The process of uterine transplantation can be summa-
rized briefly, according to Testa, et al., as follows.  First, 
the successful transplantation of the graft, including per-
fusion, or blood flow through the grafted vasculature, 
and the assessment of vital tissue present on the cervix 
in cervical biopsy to determine if the tissue is accepted 
by the recipient.  Next, a normal menstrual cycle should 
result, which means that the grafted uterus is responding 
to the recipient’s hormones.  Stable immunosuppression, 
suppression of the recipient’s immune system toward the 
foreign uterus should be maintained.  Once immunosup-
pression is achieved, a fertilized ovum is implanted.  After 
implantation that results in pregnancy, the last step is the 
successful delivery of a hopefully healthy child.  At any of 
these steps, complications can occur that would result in 
the failure of the uterine transplant (Testa et al., 2017).
 Removing the donor uterus can be done through either 
laparotomy or laparoscopy.  In a 2017 clinical trial on five 
individuals, the laparotomic removal of the donor uterus 
is detailed.  The hysterectomy performed on the donor, 
however, is more complicated than a regular hysterecto-
my, due to the vasculature that needs to be connected 
to the recipient to allow graft inflow and outflow in the 
recipient. To allow that, the vascular pedicles, tissues con-
taining the arteries and veins of the donor uterus, were 
dissected completely.  The arterial vascular pedicle of the 
graft included the uterine artery, which supplies blood 
flow to the uterus, and a part of the internal iliac artery. 
The graft uterus was drained by the uterine and ute-
ro-ovarian veins, located between the uterus and ovary. 
A transverse cut was made below the cervix, in order to 
obtain a cuff that could sufficiently be anastomosed to the 
upper vagina of the recipient. After removal, arteries were 
reconstructed, when needed, through microvascular sur-
gery (Testa et al., 2017).
As for the recipient, the external iliac artery and the 
external iliac vein were dissected and the internal iliac ar-
tery patch of the donor was grafted to the external iliac 
artery of the recipient.  For venous outflow, the uterine or 
utero-ovarian vein, depending on which provided better 
venous outflow, was sutured to the external iliac vein of 
the recipient.  Once blood flow was reperfused, the cervix 
of the new uterus was connected to the vaginal vault of the 
recipient.  Blood flow was subsequently monitored by a 
doppler blood flow monitor to assess arterial inflow to the 
transplanted uterus.  Postoperatively, for the first five days 
Doppler ultrasounds were performed, cervical biopsy was 
done on the fifth day, MRI of the uterus was performed to 
evaluate blood flow, and cervical examination under anes-
thesia was done to determine if rejection of the transplant 
tissue occurred. To suppress the immune response of the 
host to the allograft, immunosuppressive drugs such as thy-
moglobulin, tacrolimus, mycophenolic acid, and a steroid 
taper were administered (Testa et al., 2017). 
Vasculature Involved
The common iliac artery bifurcates into the internal and 
external iliac arteries.  A branch of the internal iliac artery 
is the uterine artery, which supplies blood flow to the 
uterus.  Blood flow from the uterus is via the uterine 
veins, internal iliac veins, inferior vena cava, and to the 
heart.  Figure 1 shows a diagram of the vasculature where 
blood vessels attached to the allograft are connected 
slightly differently in the recipient than expected. At point 
A, the uterine artery, with a branch of the internal iliac 
from the donor is anastomosed to the external iliac ar-
tery, instead of the recipient’s own internal iliac artery.  At 
point B, the uterine vein of the donor uterus is attached 
to the external iliac vein of the recipient, instead of the 
internal iliac vein. 
One of the most difficult parts of uterus transplanta-
tion is securing a good venous outflow.  In most cases, 
the uterine veins are used, which often have thin walls, 
can vary in number, and often are not shown sufficiently 
in preoperative imaging.  During surgery, their dissection 
can be tedious, can increase the risk of bleeding, and in-
creases surgery time (Testa et al., 2018).  Moreover, the 
uterine vein has multiple branches and is close to the 
Figure 1 . This schematic diagram portrays the blood vessels 
supplying and draining the allograft uterus . Point A is the 
anastomosis of the uterine artery to the external iliac artery . Point 
B is the anastomosis of the donor uterine vein to the external iliac 
vein (Testa et al ., 2017) .
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ureter, which could result in accidental bleeding or in-
jury to the ureter (Carbonnel et al., 2020).  In one 2018 
successful trial, researchers sustained an allograft through 
the utero-ovarian veins alone, without uterine veins.  The 
researchers recommended using the utero-ovarian veins 
instead of the uterine veins, which are easier to identify, 
dissect, and provide for safer surgery on the part of the 
donor.  In another clinical trial, the proximal portions of 
the utero-ovarian veins were dissected as potential extra 
venous outflow, and ended up being used along with the 
uterine veins as well, due to the thinness of the uterine 
veins of the donor (Brannstrom et al., 2020).  Further, by 
using the utero-ovarian veins instead of uterine veins, a 
robotic laparoscopic approach is more feasible, which will 
again increase the safety and ease for the donor (Testa et 
al., 2018).  Also, the ovarian veins are more distant from 
the ureter, so surgeons will not be concerned about inad-
vertent damage to them (Carbonnel et al., 2020).  There 
can, though, be negative repercussions for the donor as-
sociated with using the ovarian veins as venous outflow. 
In transplant procedures done in both India and China, 
removal of the ovarian veins required bilateral oophorec-
tomy, removal of the ovaries.  The donor women were 
premenopausal, which increases their risk of morbidity 
and mortality (Brannstrom et al., 2020).  However, using 
ovarian veins for venous outflow still need to be further 
researched in the future to determine whether uterus 
outflow can in all cases be sufficiently maintained using 
the ovarian veins alone (Carbonnel et al., 2020).
Wait Time Between Transplant and Surgery
Common convention for many of the different uter-
us transplant trials has been to wait one year between 
transplantation and attempt at pregnancy, similar to 
other solid organ transplants.  In a 2019 study, for ex-
ample, embryo transfers were done starting at least 12 
months post-transplant, and were done in months 13, 
16, 19, and 23, until the last transfer resulted in clinical 
pregnancy  (Chmel et al., 2019).  This convention arose 
out of a recommendation from the American Society of 
Transplantation which suggested that recipients of organ 
transplants wait one year between the transplant and 
conception to decrease any risks that may result, such as 
acute rejection to the recipient, infection that could harm 
the fetus, immunotherapy that could potentially be toxic 
to the fetus, and to be sure that the allograft is functioning 
properly (Johanesson et al., 2019).
However, women who receive uterus transplants 
are generally healthy individuals whose surgical recov-
ery should resemble that of any surgical intervention. 
There is no reason to believe that tissue healing would 
be impaired, and immunosuppression does not seem to 
hinder tissue healing (Testa et al., 2018). Further, a uterine 
transplant, unlike other organ transplants, is not meant to 
be a long-term functioning transplant.  Its longevity is for 
about five years and for a maximum of two pregnancies 
(Johanesson et al., 2019). Some suggest that there is no 
scientific basis for waiting a year between transplant and 
embryo transfer, especially because immunosuppression 
must be terminated as soon as possible, to avoid renal 
failure, which could be a risk of long-term immunosup-
pression.  Decreased time on immunosuppressants also 
reduces costs and decreases waiting time for the recipi-
ent to give birth to her baby.  In their clinical trial, embryo 
transfer was done before the six month post surgery 
mark, and yielded successful results (Testa et al., 2018).  
To provide a groundwork for the amount of time to be 
waited, researchers laid down conditions to be met in the 
recipient, which if achieved, should be a signal to begin 
embryo transfer, as opposed to giving a generalized time 
recommendation for all uterine transplant procedures. 
The patient criteria are given in order as follows.  First, 
graft function should be stable.  An indication of graft sta-
bility would be menstruation, as it is a sign that the foreign 
uterus is responding to the recipient’s hormones.  Next, 
the absence of any acute rejection, which is determined 
via cervical biopsy.  Finally, stable immunosuppression 
achieved with low teratogenic, or carcinogenic, risk, and 
the recipient is at low risk for opportunistic infection, 
which is generally associated with those who undergo 
transplantation.  Once these conditions are met, embryo 
transfer should begin as soon as possible, even as early 
as three months post-transplant if the recipient is ready 
(Johanesson et al., 2019).
Complications in Pregnancy and Post-Operatively
Generally, pregnancies resulting from uterine transplanta-
tion do not reach full-term.  However, many studies have 
been successful in which participants have carried close 
to term.  In the first successful clinical study in Sweden, 
mean delivery for the six patients was at 35 weeks ges-
tation.  Besides the difficulty in reaching full term, there 
are some other pregnancy complications that have aris-
en.  Some patients from the previously mentioned study 
experienced preeclampsia.  It is possible though, that the 
preeclampsia, preterm delivery, and delivery by cesarean 
section may be related to the original infertility; MRKH 
sometimes presents with renal defects, such as having 
a solitary kidney, which could cause extra stress to the 
recipient during pregnancy, and has been generally associ-
ated with higher risk for preterm delivery, preeclampsia, 
and cesarean section (Kisu et al., 2018).
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Other major complications that have arisen post-oper-
atively in recipients include urinary tract infections, throm-
bosis, and hematoma.  The risk of thrombosis is because 
the vessels that are anastomosed are generally narrower 
and can get obstructed more easily than vessels attached in 
other organ transplants.  Hematoma could be the result of 
inadequate hemostatic processing, or cessation of bleed-
ing.  Care must be taken with re-bleeding from capillaries 
that are unligated or bleeding from the vaginal cuff (Kisu 
et al., 2018).  Also, in one particular clinical study, vaginal 
stenosis, vesicovaginal fistula, herpes, and cytomegalovirus 
were complications experienced by some of the recipients. 
Vesicovaginal fistulae can occur more frequently in patients 
with MRKH who have a neovagina, which is constructed 
due to an underdeveloped or absent vagina, and which 
needs to be separated from the bladder during surgery. 
This could lead to a fistula, or an opening between the 
bladder and vagina (Kisu et al., 2018).
Immunosuppressants During Pregnancy
Since the transplanted uterus is from a foreign donor, 
the recipient needs to be on immunosuppressive drugs 
to prevent her own immune system from mounting a 
response against the uterus.  There have been different 
recommendations as to the type of drug, based on trials 
from both pregnant women on immunosuppressants due 
to uterus transplants and other organ transplants.  The 
importance here is that the immunosuppressive drug 
should not be toxic to the developing fetus.  Therefore 
care must be taken to either prescribe immunosuppres-
sants that are not fetotoxic, or at least halt fetotoxic 
immunosuppressants when the uterus recipient begins 
embryo transfer. One immunosuppressive drug that has 
been implicated in spontaneous abortion in the first 
trimester and congenital abnormalities of the fetus is 
mycophenolate salts, which come in two different prod-
rugs, mycophenolate mofetil and mycophenolate sodium, 
that release the compound mycophenolic acid. The FDA 
classifies this drug as a Category D drug, meaning that 
there is evidence that it can cause risk to the fetus during 
pregnancy (Ponticelli et al., 2018). Therefore, if it is used 
following the transplant, there must be a waiting period 
afterward before embryo transplant begins.  In one uter-
ine transplant trial, mycophenolate mofetil was taken out 
entirely from the maintenance immunosuppression to 
decrease the time exposed to toxic medications for the 
fetus.  They were thus able to expedite the waiting time 
before embryo transfer.  Another drug, thymoglobulin, 
is considered a category C drug, meaning it is current-
ly unknown if risk exists to the fetus. Therefore, there 
should also be a wait time between pregnancy and usage 
of thymoglobulin in immunosuppressive therapy.  Other 
common immunosuppressants such as corticosteroids, 
azathioprine, and calcineurin inhibitors appear to be safe 
in doses prescribed for transplant recipients and are 
not associated with increased risk of congenital defects 
(Johanesson et al., 2019).
Reasons for Rejection of Transplanted Uterus
Although in some cases there is not a clear reason why 
the graft failed and rejection occurred, different studies 
have hypothesized reasons for the difference in outcome. 
A conclusion was that uterus pathology and venous out-
flow were largely responsible for three graft failures that 
occurred. The authors explained that assessment of vas-
culature preoperatively could be improved. Thus, imaging 
could be used to eliminate uteri with vasculature that is 
unsuitable for a uterus transplant. They explain that using 
a CT angiogram, while helpful in showing arterial blood 
flow, was not sufficient in their study to tell the length and 
diameter of veins. This was significant because a large part 
of the donor hysterectomy surgery time was spent in dis-
section of the uterine vein, which can taper into thinner 
tributaries where it joins with the internal iliac vein, even 
though it may appear satisfactory near the uterine body. 
The researchers concluded that MRI with venous phase 
would have been a better choice in imaging to view the 
uterine veins (Testa et al., 2017). Similarly, the research-
ers explained that the arterial vasculature was not of the 
expected quality; in some patients arterial pathology was 
present. In the preoperative imaging, the vessels appeared 
patent, however; in the three grafts that failed in their 
study, there was severe arterial disease present.  In one 
donor specifically there was thickening that resulted in 
over a fifty percent decrease in luminal size. Additionally, 
the researchers noted that in the first two of the five 
patients studied there was a downward kinking of the 
vein if the anastomosis was to the superior aspect of the 
host external iliac vein. In the other three patients they 
switched the venotomy position of the external iliac vein 
to the medial aspect to avoid kinking.  Further, the re-
searchers observed that procuring a patch of the internal 
iliac with the uterine vein provided a vessel with thicker 
and stronger walls.
Another potential reason that contributed to the failure 
of one of the transplants was the variation in size between 
the large cervix size of the donor and small size of the vag-
inal vault of the recipient, which made it difficult for vagi-
nal anastomosis. The researchers believed that the limited 
space, due to the larger cervix size contributed to the graft 
congestion, poor venous outflow, and pathologies present 
ultimately resulted in transplant rejection (Testa et al., 2017).
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As far as immune-system induced rejection, ostensibly, 
since the uterus carries a non-self, it would appear that 
pregnant uterus should have some immune tolerance. 
However, cervical biopsies have shown rejection in some 
cases post-operatively.  In one transplant study, 13 out of 
163 cervical samples taken from seven patients showed 
mild rejection after transplantation.  Steroid therapy helped 
patients reach remission, yet some developed rejection 
complications again during pregnancy, which is more dif-
ficult to manage and measures need to be developed for 
the future for treatment-resistant rejection.  Some suggest 
that the contact that the uterus has with the external en-
vironment, through the vagina, is responsible for the pros-
pect of rejection of the allograft (Kisu et al., 2018).
Ethical Implications
The practice of uterine transplantation is a subject of 
great ethical controversy.  As a non-life-saving procedure, 
it differs from other forms of organ transplantation, which 
are considered essential.  However, there are those who 
categorize it similarly to face, hand, or other vascularized 
transplants, which though not life-saving transplants, are 
nonetheless justifiable organ transplants for improving 
the quality of life of recipients.  Additionally, although 
uterine transplantation is considered an elective treat-
ment, it stands as the only medical treatment for abso-
lute uterine factor infertility.  Surrogacy and adoption are 
options for women with infertility, but for some women 
they are not adequate substitutes for the experience of 
pregnancy (Bayefsky and Berkman, 2016).
Once uterine transplantation transitions from an ex-
perimental procedure to a common clinical one, there 
are multiple points that will need to be taken into con-
sideration.  There will likely be a shortage of uteri for 
donation. While there are those who argue that uteri 
from women who have had hysterectomies should be 
used to supply organs for uterine transplants, often hys-
terectomies are done to remove unhealthy uteri, and 
are done in a way that does not leave the organ fit for 
transplantation, so those would not be feasible sources of 
uteri. Uterine transplants must also come with sufficient 
vasculature, which is generally not removed in an average 
hysterectomy.  Given that there will likely be a greater de-
mand than the supply of uteri, there will need to be a way 
to prioritize some individuals over others.  As far as for 
other organ transplants, such as heart, kidneys, or lungs, 
pediatric or younger individuals are generally prioritized 
over older adults, because adults have experienced child-
hood, and pediatric patients, if not given the transplant, 
may never have that experience.  In the same vein, it is 
sensible to say that when prioritizing women for uterine 
transplants, women who are of childbearing age should 
be given precedence over both women who are older 
and beyond reproductive age and adolescents who have 
not yet reached childbearing age.  However, in choosing 
between younger and older individuals within the span of 
child-bearing, women who are nearing the end of their 
childearing years should be given priority over younger 
individuals so that they can have their chance to have 
children before they age out of their childbearing years, 
while the younger individuals still have time.  “Normal 
childbearing age” is considered between the ages of 
15-49 according to the World Health Organization, and 
a standard for recipients should be within those limits.  A 
national standard, in limiting the age of recipients, should 
reflect medical assessment of the surgical and obstetric 
risks incurred to women of different ages, the risk to the 
fetus, and the probability of successful pregnancy.
Further, there must also be some sort of child-rearing 
capacity standard created that potential candidates will 
demonstrate before allocating a uterus, similar to how 
women who wish to adopt must meet certain criteria.
In differentiating between women with uterine infertil-
ity, different candidates have different needs with regard 
to treatment.  Some need only a transplant, while others 
may need IVF, egg donation, or sperm donation.  It is rea-
sonable to suggest that those with the least interventions 
necessary to achieve pregnancy should be given priority, 
in the same vein as choosing candidates for transplanta-
tion who are more likely to have successful transplanta-
tion (Bayefsky and Berkman, 2016).
Putting aside the controversy associated with can-
didates for treatment, there is also dispute about the 
source for donor uteri.  Procuring a uterus from a live 
donor can incur risk to the individual.  While there are 
innovations to the process of securing a uterus, through 
laparoscopic robotic procedures, as opposed to open lap-
arotomy, advancements will need to be made to decrease 
the risks for the donor.  Also, the advancement of using 
cadaveric or nonliving donor uteri will be important in 
fueling the future of uterine transplantation, though it will 
be a source of contention as to whether a person who 
has lost all brain function and is considered “brain dead,” 
will be categorized as deceased along with those whose 
circulatory and respiratory systems have failed.
Conclusion
Uterine Transplantation is a possible radical and innova-
tive surgical option for those who suffer from absolute 
uterine factor infertility.  Many studies have been done 
world-wide, which have contributed to the available data 
on the risks and ways to improve the process. While 
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there is no one factor that contributes to the rejection 
or success of a uterine transplant, certain factors have 
been implicated in the reasons for transplant failure or 
success.  Vasculature problems can account for some 
reasons for rejection, such as sclerotic vessels, or using 
thin-walled uterine veins that are difficult to dissect and 
may not provide adequate venous outflow.  Adequate im-
aging should be done to identify vessel pathology and the 
acceptability of the donor vasculature.   The possibility 
of using the utero-ovarian veins might be a good alter-
native to the uterine veins, though it can cause the onset 
of menopause and may increase morbidity in premeno-
pausal women, due to oophorectomy.  Also, mismatch in 
vaginal-cervix size between the donor and recipient may 
be problematic. Wait time between transplant and em-
bryo transfer and immunosuppressants are other factors 
to take into account. Advances in using deceased donor 
uteri, which allows harvesting longer length of vessels, or 
using live donor uteri procured through laparoscopic ro-
botic assisted hysterectomy can streamline the process. 
Although a promising treatment for those with absolute 
infertility, more research needs to be conducted to en-
sure its safety and to standardize the procedure.
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